Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ).
Resmed Inc has filed a notice of proposed sale of securities under Rule 144, indicating that Brett Sandercock, an officer of the company, plans to sell 1,000 shares of common stock. The sale is scheduled for June 2, 2025, with an aggregate market value of $243,780. This move follows previous sales by Sandercock in March and April 2025, reflecting ongoing transactions that may impact the company’s stock liquidity and stakeholder interests.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$33.70 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
Resmed Inc operates in the healthcare industry, primarily focusing on the development and manufacturing of products related to sleep disorders, respiratory care, and connected health solutions. The company is known for its innovative devices and software applications that aim to improve patient outcomes and enhance the quality of life for individuals with chronic respiratory conditions.
Average Trading Volume: 1,317,793
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$55.21B
For an in-depth examination of RMD stock, go to TipRanks’ Stock Analysis page.